Document Detail


Multicentre trial of naproxen and phenylbutazone in acute gout.
MedLine Citation:
PMID:  843115     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Naproxen 750 mg as a single dose followed by 250 mg three times daily has been compared with phenylbutazone 200 mg four times daily for 48 hours followed by 200 mg three times daily for treatment of acute gout in an open study on 41 patients. The drugs were equally effective with few and relatively mild side effects. Naproxen is a useful alternative agent for the treatment of acute gout.
Authors:
R A Sturge; J T Scott; E B Hamilton; S P Liyanage; A S Dixon; J Davies; C Engler
Related Documents :
6406435 - Evaluation of the safety and efficacy of bupropion in depression.
2529295 - Response of panic disorder to fixed doses of alprazolam or imipramine.
12815555 - Oxymetholone for the treatment of hiv-wasting: a double-blind, randomized, placebo-cont...
3310585 - Efficacy and tolerance of ethmozine (moricizine hcl) in placebo-controlled trials.
9239805 - Effect of activated charcoal on rifampicin absorption in man.
1310965 - Potential improvement of three dimension treatment planning and proton therapy in the o...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  36     ISSN:  0003-4967     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  1977 Feb 
Date Detail:
Created Date:  1977-04-15     Completed Date:  1977-04-15     Revised Date:  2009-11-18    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  80-2     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adult
Aged
Female
Gout / drug therapy*
Humans
Male
Middle Aged
Naphthaleneacetic Acids / therapeutic use*
Naproxen / therapeutic use*
Phenylbutazone / therapeutic use*
Chemical
Reg. No./Substance:
0/Naphthaleneacetic Acids; 22204-53-1/Naproxen; 50-33-9/Phenylbutazone
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Radiographic changes in early rheumatoid disease.
Next Document:  HLA antigens in systemic lupus erythematosus.